Can Mounjaro (tirzepatide) cause high anion gap metabolic acidosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mounjaro (Tirzepatide) and High Anion Gap Metabolic Acidosis

Mounjaro (tirzepatide) itself is not directly associated with high anion gap metabolic acidosis based on current evidence, unlike SGLT2 inhibitors which can cause euglycemic ketoacidosis. While GLP-1 receptor agonists like Mounjaro have various side effects, high anion gap metabolic acidosis is not a recognized direct complication of this medication class 1.

Mechanisms of High Anion Gap Metabolic Acidosis

High anion gap metabolic acidosis occurs when there is accumulation of acid anions in the blood, resulting in an elevated anion gap (typically >12 mEq/L). Common causes include:

  • Lactic acidosis (tissue hypoperfusion, sepsis)
  • Ketoacidosis (diabetic, alcoholic, starvation)
  • Renal failure (uremic acidosis)
  • Toxic ingestions (methanol, ethylene glycol, salicylates)
  • Medication-induced acidosis 2, 3

Medication Classes Known to Cause High Anion Gap Metabolic Acidosis

Several medications can cause high anion gap metabolic acidosis:

  • SGLT2 inhibitors: Can cause euglycemic diabetic ketoacidosis, especially perioperatively 1
  • Biguanides (metformin): Can cause lactic acidosis, particularly in renal impairment
  • Salicylates: Direct toxicity causing metabolic acidosis
  • Alcohols and glycols: Metabolized to organic acids 4

Mounjaro (Tirzepatide) and Acid-Base Balance

Tirzepatide is a dual GIP/GLP-1 receptor agonist that:

  • Enhances glucose-dependent insulin secretion
  • Decreases glucagon secretion
  • Slows gastric emptying
  • Reduces appetite

Unlike SGLT2 inhibitors, which can cause ketoacidosis by:

  • Lowering glucose concentrations
  • Changing insulin/glucagon ratio
  • Predisposing to ketosis during physiological stress 1

GLP-1 receptor agonists like tirzepatide do not have this mechanism of action and are not associated with ketoacidosis or high anion gap metabolic acidosis in the current literature.

Clinical Considerations

When evaluating unexplained high anion gap metabolic acidosis in patients on multiple medications:

  • Calculate and correct anion gap for albumin level
  • Compare to patient's baseline anion gap rather than population normal
  • Assess relationship between changes in bicarbonate and anion gap
  • Consider uncommon causes like 5-oxoproline acidosis if common causes are ruled out 3

Monitoring Recommendations

For patients on Mounjaro:

  • Regular monitoring of renal function is prudent, as impaired kidney function can lead to metabolic acidosis
  • Be vigilant for symptoms like nausea, vomiting, malaise, and confusion that could indicate an underlying acid-base disturbance
  • If acidosis develops, perform comprehensive workup including arterial blood gases, serum electrolytes with calculated anion gap, serum ketones, lactate, glucose, and renal function tests 2

Important Distinctions

While SGLT2 inhibitors have a documented risk of euglycemic ketoacidosis (with an odds ratio of 1.48 compared to non-users) 1, GLP-1 receptor agonists like Mounjaro do not share this risk profile. The perioperative management guidelines for these medication classes differ accordingly, with SGLT2 inhibitors requiring careful perioperative management to prevent ketoacidosis.

If a patient on Mounjaro develops high anion gap metabolic acidosis, clinicians should investigate other common causes rather than attributing it directly to the medication.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Lactic Acidosis Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Use of anion gap in the evaluation of a patient with metabolic acidosis.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2014

Research

Drug and chemical-induced metabolic acidosis.

Clinics in endocrinology and metabolism, 1983

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.